Antidote: Finding a new flu vaccine

The day will come soon when all flu vaccines are grown in cell culture, using genetic splicing techniques to provoke and immunologic (antibody) response rather than growing actual viruses in hen eggs.

For this year's H1N1 swine flu pandemic, we are relying mostly on old technology from the 1950s. This involves growing the flu virus in hen eggs, and extracting a dead virus (inactivated) for use in the vaccine. The new swine flu vaccine appears to be well tolerated, and will likely only be a problem for those with severe egg allergies. It will be important for healthcare workers, children, pregnant women and those with chronic conditions to receive it first.
It is ironic to think that the fact that the vaccine is being made by tried and true techniques is the very fact I and other flu experts are using to reassure people. This technology has been used for several decades safely. Fear of vaccines have often proven to be well out of proportion to the real risk. Administering a vaccine always comes down to a cost-benefit analysis, where the goal is to protect a population where more risk is to be found in the disease than in the vaccine given to protect you.

Vaccine manufacturers have a tough job. They must ensure sterility with careful precautions, and weather being maligned by the media and anxious parents over something like the mercury-containing additive thimerosal, which study after study has found to be safe. Vaccines are not very profitable, but they are important, and vaccine makers should be applauded rather than subject to knee-jerk criticism.

Marc Siegel, MD, is an internist and professor of medicine at New York University and the author of False Alarm: The Truth About the Epidemic of Fear
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.